|Budget Amount *help
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|Outline of Final Research Achievements
We established iPS cells derived from health donor (WT-iPS), severe congenital neutropenia (SCN), and cyclic neutropenia (CyN). And we established differentiation therapy from iPS cells to hematopoietic stem cells and granuloccytes without serum and feeder cells.
The colony formation and cell proliferation of CD34 positive cells derived from SCN-iPS were decreased compared with WT-iPS or CyN-iPS, suggesting the possibility that the ability of hematopoiesis and proliferation were impaired in the early stage of hemoangiogenic progenitor. There were no definite difference in the cell localization of elastase and the expression of BIP protein between SCN-iPS, CyN-iPS and WT-iPS. These date suggest that the impairment in the early proliferation stage cause the severe neutropenia.